Cover Image
市場調查報告書

血栓性栓塞症:開發平台分析

Thromboembolism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200494
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
血栓性栓塞症:開發平台分析 Thromboembolism - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 101 Pages
簡介

血栓是在血液中損壞或移動稱為血栓性栓塞症。症狀為有熱的感覺、水腫、紅斑等,也有胸壁或腳上靜脈擴張(方面副靜脈)。危險因素有高血壓,真性糖尿病,抽煙,高膽固醇值等。治療用抗凝固劑、進行血栓溶解治療、手術等。

本報告提供血栓性栓塞症的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

血栓性栓塞症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • AstraZeneca PLC
  • Bayer AG
  • Cereno Scientific AB
  • CSL Limited
  • 第一三共
  • Gamma Therapeutics, Inc.
  • Green Cross Corporation
  • Isis Pharmaceuticals, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regado Biosciences, Inc.
  • Sanofi

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AZ-12971554
  • betrixaban
  • C-3
  • CSL-3F7
  • edoxaban tosylate
  • Gammarin
  • GCC-2107
  • ISIS-FXIRx
  • Lysimab
  • Protein for Thromboembolism and Blood Coagulation
  • REG-2
  • rivaroxaban
  • semuloparin
  • Small Molecules to Inhibit HDAC for Thromboembolism
  • TAP-ANV
  • YG-001

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8289IDB

Summary

Global Markets Direct's, 'Thromboembolism - Pipeline Review, H2 2016', provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thromboembolism
  • The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects
  • The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thromboembolism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thromboembolism Overview
  • Therapeutics Development
    • Pipeline Products for Thromboembolism - Overview
    • Pipeline Products for Thromboembolism - Comparative Analysis
  • Thromboembolism - Therapeutics under Development by Companies
  • Thromboembolism - Therapeutics under Investigation by Universities/Institutes
  • Thromboembolism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thromboembolism - Products under Development by Companies
  • Thromboembolism - Products under Investigation by Universities/Institutes
  • Thromboembolism - Companies Involved in Therapeutics Development
    • Bayer AG
    • Cereno Scientific AB
    • China Biologic Products, Inc.
    • Daiichi Sankyo Company, Limited
    • F. Hoffmann-La Roche Ltd.
    • Gamma Therapeutics, Inc.
    • GlycoMimetics, Inc.
    • Green Cross Corporation
    • Ionis Pharmaceuticals, Inc.
    • Portola Pharmaceuticals, Inc.
  • The International Biotechnology Center (IBC) Generium
    • Thromboembolism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alteplase biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • antithrombin III (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • betrixaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edoxaban tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gammarin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GCC-2107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMI-1271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-FXIRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lysimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAP-ANV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YG-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thromboembolism - Dormant Projects
  • Thromboembolism - Discontinued Products
  • Thromboembolism - Product Development Milestones
    • Featured News & Press Releases
      • May 27, 2016: Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
      • May 23, 2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on Betrixaban at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting
      • Apr 06, 2016: Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis SSC Meeting 2016 on May 27, 2016
      • Mar 30, 2016: Bristol-Myers Squibb And Pfizer Announce Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology'S 65Th Annual Scientific Session
      • Mar 24, 2016: Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
      • Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer
      • Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015
      • Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015
      • Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients
      • Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
      • Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
      • Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
      • Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
      • Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots
      • Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thromboembolism, H2 2016
  • Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Thromboembolism - Pipeline by Bayer AG, H2 2016
  • Thromboembolism - Pipeline by Cereno Scientific AB, H2 2016
  • Thromboembolism - Pipeline by China Biologic Products, Inc., H2 2016
  • Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2016
  • Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2016
  • Thromboembolism - Pipeline by Green Cross Corporation, H2 2016
  • Thromboembolism - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Thromboembolism - Dormant Projects, H2 2016
  • Thromboembolism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Thromboembolism, H2 2016
  • Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top